Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 44376 - 44400 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Fulvestrant	Approved Investigational	DST	667	upregulated	fulvestrant results in increased expression of DST mRNA	6p12.1	A21116
Fulvestrant	Approved Investigational	DYNLL1	8655	upregulated	fulvestrant results in increased expression of DYNLL1 mRNA	12q24.31	A20482
Fulvestrant	Approved Investigational	DYRK2	8445	upregulated	fulvestrant results in increased expression of DYRK2 mRNA	12q15	A21106
Fulvestrant	Approved Investigational	E2F1	1869	downregulated	fulvestrant results in decreased expression of E2F1 mRNA	20q11.22	A22730
Fulvestrant	Approved Investigational	EFNA1	1942	upregulated	fulvestrant results in increased expression of EFNA1 mRNA	1q22	A21102 A21106
Fulvestrant	Approved Investigational	EGR3	1960	downregulated	fulvestrant results in decreased expression of EGR3 mRNA	8p21.3	A21106
Fulvestrant	Approved Investigational	EIF2S1	1965	downregulated	fulvestrant results in decreased expression of EIF2S1 mRNA	14q23.3	A20479
Fulvestrant	Approved Investigational	EIF5	1983	downregulated	fulvestrant results in decreased expression of EIF5 mRNA	14q32.32	A20479
Fulvestrant	Approved Investigational	ELOB	6923	downregulated	fulvestrant results in decreased expression of ELOB mRNA	16p13.3	A20479
Fulvestrant	Approved Investigational	ELOVL5	60481	downregulated	fulvestrant results in decreased expression of ELOVL5 mRNA	6p12.1	A20479
Fulvestrant	Approved Investigational	EPHA1	2041	upregulated	fulvestrant results in increased expression of EPHA1 mRNA	7q34-q35	A20482
Fulvestrant	Approved Investigational	EPHA4	2043	upregulated	fulvestrant results in increased expression of EPHA4 mRNA	2q36.1	A21106
Fulvestrant	Approved Investigational	ERBB2	2064	upregulated	fulvestrant results in increased expression of ERBB2 mRNA	17q12	A21102
Fulvestrant	Approved Investigational	ESPL1	9700	downregulated	fulvestrant results in decreased expression of ESPL1 mRNA	12q13.13	A22729
Fulvestrant	Approved Investigational	ESR1	2099	downregulated	fulvestrant results in decreased expression of ESR1 mRNA	6q25.1-q25.2	A21158
Fulvestrant	Approved Investigational	ESR1	2099	upregulated	fulvestrant results in increased expression of ESR1 mRNA	6q25.1-q25.2	A21186
Fulvestrant	Approved Investigational	ESRRA	2101	upregulated	fulvestrant results in increased expression of ESRRA mRNA	11q13.1	A21141
Fulvestrant	Approved Investigational	F2R	2149	upregulated	fulvestrant results in increased expression of F2R mRNA	5q13.3	A20482
Fulvestrant	Approved Investigational	FASLG	356	downregulated	fulvestrant results in decreased expression of FASLG mRNA	1q24.3	A22735
Fulvestrant	Approved Investigational	FASLG	356	upregulated	[fulvestrant results in increased expression of TGFB1 protein] which results in increased expression of FASLG mRNA	1q24.3	A22735
Fulvestrant	Approved Investigational	FBXO5	26271	downregulated	fulvestrant results in decreased expression of FBXO5 mRNA	6q25.2	A22729
Fulvestrant	Approved Investigational	FGF9	2254	downregulated	fulvestrant results in decreased expression of FGF9 mRNA	13q12.11	A21281
Fulvestrant	Approved Investigational	FHL2	2274	downregulated	fulvestrant results in decreased expression of FHL2 mRNA	2q12.2	A21106
Fulvestrant	Approved Investigational	FLNC	2318	downregulated	fulvestrant results in decreased expression of FLNC mRNA	7q32.1	A20479
Fulvestrant	Approved Investigational	FOS	2353	downregulated	fulvestrant results in decreased expression of FOS mRNA	14q24.3	A21102

Displaying entries 44376 - 44400 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability